Dan Timofte, Mihaela Blaj, Florin Petrariu, Lidia Ionescu
Pancreatic ductal adenocarcinoma is one of the most common malignant disease of the pancreas having its origin in the ductal epithelium. With an increasing incidence, it is considered one of the most aggressive human tumours. It has a high degree of lethality, survival at 5 years being reported to be up to 4%. This poor outcome is due to both a low specificity of onset symptoms (e.g. the disease is usually diagnosed in advanced stages) and also to a lack of tumour markers in order detects the presence of the tumour in the early stage, as well as the absence of effective non-surgical treatment modalities. Up to now, surgery is the only treatment modality that can provide a greater chance of survival, but unfortunately is an option only for about 15% of patients. The resections for the pancreatic cancer have entered the therapeutic arsenal for almost 70 years, but despite hundreds of reports written about this topic, there is no unanimity on the effectiveness of the resection. In this way, we will describe here some current aspects and survival numbers related to resectability in the pancreatic cancer.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 